AQST

Aquestive TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

Current thesis

Composite grade F from latest DB weights. Momentum 12.8 / Value 41.1

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.1.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

— · Net —

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net —

Target $8.75

Why

Momentum13 · Δ7d -4.6

Value41 · Δ7d -0.1

SentimentN/A · Δ7d -

So what

Weak posture. Prioritize risk control and patience.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

40% active weight

Current posture

7d trendSoftening

Δ7d

-4.6

Δ21d

-32.8

Value

60% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade F. Momentum 12.8 / Value 41.1

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$516.92M

Beta

1.65

Shares Out

125.47M

P/E (TTM) · Derived

-5.3

P/S (TTM)

17.51

P/FCF (TTM) · Derived

-10.60

Rev YoY

+65.7%

EPS YoY

-72.6%

Gross Margin

+63.5%

Op Margin

-128.6%

Net Debt

$10.28M

Current Ratio

4.10

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology